This article is over a month old and may contain outdated advice from the authorities regarding coronary heart disease.
Stay up to date in NRK’s overview, or through FHIs nettsider.
–
On Friday afternoon, the case was published in The New England Journal of Medicine.
A total of eleven medical professionals have been involved in Norway. Chief physician and professor Pål André Holme at Rikshospitalet has led the work. The researchers have chosen to call the condition “vaccine-induced immune thrombotic thrombocytopenia”, writes Aftenposten.
Chief physician and professor Pål André Holme at Rikshospitalet has led the work.
Photo: Terje Pedersen / NTB
–
In Norway, 133,870 people have received the AstraZeneca vaccine. Six people, five women and one man have experienced different variants of the same disease picture.
Four people have died. Blood clot patients in Norway have been between 32 and 54 years old. All are health workers.
The vaccination was paused
On March 11, the vaccination was with the vaccine from AstraZeneca paused in Norway. Since then, we have received around 170,000 new doses. Whether the doses will be used in this country is still uncertain.
We will get the answer to what happens next on 15 April. Then FHI must have decided whether they want to resume use. By that time, there will be about 200,000 vaccine doses in stock of the vaccine, according to FHI.
FHI’s director of infection control, Geir Bukholm, has previously said that the pace of vaccination in Norway will only be delayed by a few weeks if the vaccine is not used again. However, it requires the other manufacturers to deliver as expected.
Strong immune response
Platelets are small, colorless, and nucleated cell fragments in the blood. They are of great importance in preventing or stopping bleeding. The disease comes after a strong immune response from the vaccine. “All patients had high levels of antibodies to platelet factor 4,” the article states.
– Such antibodies can activate and aggregate platelets. Then you get a platelet drop and blood clots, UNN researcher Ingvild Sørvoll told Aftenposten before Easter.
The researchers will meet the press at a digital press conference about the case at Zoom on Saturday at 11, Oslo University Hospital reports in a press release on Saturday night.
At the press conference, the last author, chief physician and professor Pål André Holme (OUS) and the co-authors Nina Haagenrud Schultz (OUS), Ingvild H. Sørvoll (UNN) and Maria Therese Ahlén (UNN) will present.
–
